TrialBritish journal of haematology2011

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Elliott Vichinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.